Use of diuretics in hypertensive patients with metabolic disturbances

Abstract


The multicenter research MERSY (Moxonidine Efficacy on blood pressure Reduction revealed in a metabolic SYndrome population) finished in 2008 was devoted to an assessment of long-term safety and efficiency of agonist I2-imidazolin receptors – moxonidine in patients with arterial hypertension and metabolic syndrome (in the general group and in advance defined subgroup of patients in a postmenopause). In 2013 final international results of the research MERSY which showed high antihypertensive activity of moxonidine, and also its positive influence on metabolic parameters and mass of a body were published.

Full Text

Restricted Access

About the authors

Yuliya Valer'evna Zhernakova

Irina Evgen'evna Chazova

References

  1. Жернакова Ю.В. Клиническая характеристика различных вариантов течения метаболического синдрома и возможности влияния антигипертензивной терапии на уровень артериального давления, состояние углеводного, липидного обменов и выраженность ожирения у больных артериальной гипертонией и метаболическим синдромом. Автореф. дис.. д - ра мед. наук. М., 2012.
  2. Шарипова Г.М. Особенности поражения органов - мишеней у больных артериальной гипертонией в зависимости от наличия и отсутствия метаболического синдрома. Автореф. дис.. д - ра мед. наук. М., 2009.
  3. Reaven G.M. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607.
  4. Randle P.J, Garland P, Hales C et al. The glucose - fatty acid cycle: its role in insulin sensitivity and metabolic disturbance of diabetes mellitus. Lancet 1963; 1: 785–9.
  5. Uysal K.T, Wiesbrock S.M, Marino M.W et al. Protection from obecity – induced insulin resistance in mice. Lacking TNF - a function. Nature 1997; 389: 610–4.
  6. Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–7.
  7. Ernsberger P. Pharmacology of moxonidine: and I1 - imidazoline receptor agonist. J Cardiovasc Pharmacol 2000; 35 (7 Suppl. 4): s27–41.
  8. Rosen P, Ohhy P, Gleichmann H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructoseied rat. J Hypertens 1997; Suppl. 15: s31–8.
  9. Ernsberger P, Ishizuka T, Liu S et al. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). J Pharmacol Exp Ther 1999; 288: 139–47.
  10. Kirch W, Hutt H.J, Planitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients. J Clin Pharmacol 1990; 30: 1088–95.
  11. Mitrovic V, Patyna W, Huting J et al. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991; 5 (6): 967–72.
  12. Friedman J.E, Ishizuka T, Liu S et al. Antihyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. Blood Press 1998; Suppl. 3: 32–9.
  13. Чазова И.Е., Мычка В.Б. Новые возможности в лечении больных с метаболическим синдромом. Результаты исследования ALMAZ. Системные гипертензии. 2006; 8 (2): 456–65.
  14. Chazova I, Schlaich M.P. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY Study. Intern J Hypertens 2013; 1–9.
  15. Sharma A.M, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a post marketing surveillance study. J Hum Hypertens 2004; 18: 669–75.
  16. Prichard B.N.C, Simmons R, Rooks J et al. A double - blind comparison of moxonidine and atenolol in the management of patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1992; 20 (Suppl. 4): s45–9.
  17. Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992; 20 (Suppl. 4): s42–4.
  18. Trieb G, Jager B, Hughes P.R et al. Long - term evaluation of the antihypertensive efficacy and tolerability of the orally - acting imidazoline I1-receptor agonist moxonidine. Eur J Clin Res 1995; 7: 227–40.
  19. Kjeldsen S.E, Naditch-Brule L, Perlini S et al. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the global cardio metabolic risk profile in patients with hypertension disease survey. J Hypertens 2008; 26: 2064–70.
  20. Chazova I, Almazov V.A, Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes Obes Metab 2006; 8: 456–65.
  21. James W.P, Caterson I.D, Coutinho W et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905–17.
  22. Lambert E, Sari C.I, Dawood T et al. Sympathetic nervous system activity is associated with obesity - induced subclinical organ damage in young adults. Hypertension 2010; 56: 351–8.
  23. Lambert G.W, Straznicky N.E, Lambert E.A et al. Sympathetic nervous activation in obesity and the metabolic syndrome – causes, consequences and therapeutic implications. Pharmacol Ther 2010; 126: 159–72.
  24. Mancia G, Bousquet P, Elghozi J.L et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007; 25: 909–20.
  25. Zidek W, Naditch-Brule L, Perlini S et al. Blood pressure control and components of the metabolic syndrome: the GOOD survey. Cardiovasc Diabet 2009; 8: 51.

Statistics

Views

Abstract - 22

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies